Associated Papers
Identification of additional DPYD polymorphisms that increase the risk of severe fluoropyrimidine toxicity and improved predictive accuracy when combined with previously validated variants.
Nguyen-Hoang N et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
Severe toxicity following genotype-guided reduced 5-FU dose in a heterozygous DPYD c.2846A>T carrier with stage III anal carcinoma: A case report.
Norris ML et al.
Cancer Chemotherapy and Pharmacology, 2025
Relevance of the c.557A>G variant for the implementation of DPYD pharmacogenetics in populations with Afro-Latin American ancestry.
González de la Cruz C et al.
Drug Metabolism and Personalized Therapy, 2025
Real-world study on fluoropyrimidine-related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype-guided dosing.
Peeters SLJ et al.
International Journal of Cancer, 2025
Implementing Pre-Emptive Pharmacogenetics: Impact of Early Pharmacogenetic Screening in a Pediatric Oncology Cohort of 1,151 Subjects.
Bernsen EC et al.
Clinical Pharmacology and Therapeutics, 2025
Implementation of DPYD and UGT1A1 Testing in Patients With GI Cancer: A Prospective, Nonrandomized Clinical Trial.
Tuteja S et al.
Jco Precision Oncology, 2025
Feasibility and population exposure of 5-fluorouracil using therapeutic drug monitoring (PREDICT-5FU): A multicentre clinical trial.
Glewis S et al.
British Journal of Clinical Pharmacology, 2025
Pharmacogenetic Profiling of Genes Associated with Outcomes of Chemotherapy in Omani Healthy Controls.
Al-Mahrouqi N et al.
Genes, 2025
DPYD Genotyping, Fluoropyrimidine Dosage and Toxicity: An Umbrella Review of Systematic Reviews.
Otero-Torres S et al.
Pharmaceuticals (basel, Switzerland), 2025
A Guide for Implementing DPYD Genotyping for Systemic Fluoropyrimidines into Clinical Practice.
Ho TT et al.
Clinical Pharmacology and Therapeutics, 2025
Development of an Ancestrally Inclusive Preemptive Pharmacogenetic Testing Panel.
Lteif C et al.
Clinical and Translational Science, 2025
Pharmacogenomics: DPYD and Prevention of Toxicity.
Keen J et al.
Clinical Oncology (royal College of Radiologists (great Britain)), 2025
Dihydropyrimidine enzyme activity and its effect on chemotherapy toxicity: importance of genetic testing.
Shamaei Zadeh A et al.
Cancer Chemotherapy and Pharmacology, 2025
Balance of care activity after EMA recommendation for DPYD gene testing in Galicia.
Gil-Rodríguez A et al.
Frontiers in Pharmacology, 2025
Clinical impact of pharmacogenomics in pediatric care: insights extracted from clinical exome sequencing.
Maggo S et al.
Frontiers in Genetics, 2025
Exploring a novel model for newborn genetic screening in Ningxia, northern China: A retrospective observational study.
Mao X et al.
Medicine, 2024
The Frequency of DPYD c.557A>G in the Dominican Population and Its Association with African Ancestry.
Guevara M et al.
Pharmaceutics, 2024
Pharmacogenetic-guided dosing for fluoropyrimidine (DPYD) and irinotecan (UGT1A1*28) chemotherapies for patients with cancer (PACIFIC-PGx): A multicenter clinical trial.
Glewis S et al.
Clinical and Translational Science, 2024
Pharmacogenetic analysis of structural variation in the 1000 genomes project using whole genome sequences.
Sherman CA et al.
Scientific Reports, 2024
Mapping the Pharmacogenetic Landscape in a Ugandan Population: Implications for Personalized Medicine in an Underrepresented Population.
Samarasinghe SR et al.
Clinical Pharmacology and Therapeutics, 2024
DPYD Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2024
Characterization of Reference Materials for DPYD: A GeT-RM Collaborative Project.
Gaedigk A et al.
The Journal of Molecular Diagnostics : Jmd, 2024
Letter to the Editor: Variant Coverage and Diagnostic Performance of Commercially Available DPYD Genotyping Tests in Brazil.
Suarez-Kurtz G
Journal of the National Comprehensive Cancer Network : Jnccn, 2024
DPYD genetic polymorphisms in non-European patients with severe fluoropyrimidine-related toxicity: a systematic review.
Chan TH et al.
British Journal of Cancer, 2024
Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study.
Díaz-Villamarín X et al.
Pharmaceutics, 2024
Real-World Impact of an In-House Dihydropyrimidine Dehydrogenase (DPYD) Genotype Test on Fluoropyrimidine Dosing, Toxicities, and Hospitalizations at a Multisite Cancer Center.
Nguyen DG et al.
Jco Precision Oncology, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
A systematic review and meta-analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancer.
Lingaratnam S et al.
Clinical and Translational Science, 2024
Unveiling Discrepant and Rare Dihydropyrimidine Dehydrogenase (DPYD) Results Using an In-House Genotyping Test: A Case Series.
Nguyen DG et al.
Journal of the National Comprehensive Cancer Network : Jnccn, 2024
Contradiction in Star-Allele Nomenclature of Pharmacogenes between Common Haplotypes and Rare Variants.
Ahn SH et al.
Genes, 2024
Overcoming Barriers to Discovery and Implementation of Equitable Pharmacogenomic Testing in Oncology.
Shriver SP et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2024
A New Cloud-Native Tool for Pharmacogenetic Analysis.
Yuan DY et al.
Genes, 2024
Developing DPYD Genotyping Method for Personalized Fluoropyrimidines Therapy.
Wong BYL et al.
The Journal of Applied Laboratory Medicine, 2024
Risk of Toxicity From Topical 5-Fluorouracil Treatment in Patients Carrying DPYD Variant Alleles.
Granados J et al.
Clinical Pharmacology and Therapeutics, 2024
Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity.
Larrue R et al.
The Pharmacogenomics Journal, 2024
Updated DPYD HapB3 haplotype structure and implications for pharmacogenomic testing.
Turner AJ et al.
Clinical and Translational Science, 2024
Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy.
Hertz DL et al.
Clinical Pharmacology and Therapeutics, 2023
Addressing barriers to increased adoption of DPYD genotyping at a large multisite cancer center.
Morris SA et al.
American Journal of Health-system Pharmacy : Ajhp : Official Journal of the American Society of Health-system Pharmacists, 2023
Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: What are the explanatory factors?
Arrivé C et al.
British Journal of Clinical Pharmacology, 2023
Confirmatory DPYD Testing in Patients Receiving Fluoropyrimidines Who are Suspected DPYD Variant Carriers Based on a Genetic Data Repository.
Pasternak AL et al.
Clinical Pharmacology and Therapeutics, 2023
Pharmacogenetics and Adverse Events in the Use of Fluoropyrimidine in a Cohort of Cancer Patients on Standard of Care Treatment in Zimbabwe.
Afolabi BL et al.
Journal of Personalized Medicine, 2023